ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024 Selected move-forward Phase 2 dose for IDE397 in MTAP squamous NSCLC, based on clinical efficacy observed in this indication, including multiple PRs by RECIST 1.1; and multiple PRs by RECIST 1.1 have also been observed in MTAP bladder cancer Enrollment is ongoing in the ...

SOUTH SAN FRANCISCO, Calif., May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event. RBC Capital Markets Global Healthcare Conference Tuesday, May 14th, 2024 at 3:05 PM ET Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst A live audio we ...

SOUTH SAN FRANCISCO, Calif., April 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2 ...

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/a ...

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1 Evaluating over 40 MTAP PDX preclinical models, squamous NSCLC was identified as the most sensitive tumor type to IDE397 monotherapy where ~50% of the models observed tumor regressions at 30mg/kg QD Over 100,000 global annual incidence of MTAP-deletion squamous NSCLC SOUTH SAN FRANCISCO, Calif ...

公司概况 - 公司是一家专注于发现和开发针对分子诊断选择的靶向治疗药物的精准医学肿瘤公司[12] 临床项目 - 公司最先进的临床项目是评估darovasertib（IDE196）在葡萄膜黑色素瘤（UM）中的潜在注册启动阶段2/3临床试验[13] - IDE397（MAT2A）正在进行阶段1/2临床试验，目前正在为具有MTAP基因缺失的肿瘤患者招募患者[16] - IDE161（PARG）正在进行阶段1临床试验，重点关注雌激素受体阳性（ER+）、人表皮生长因子受体2阴性（Her2-）乳腺癌等固体肿瘤[20] - GSK正在评估GSK101与niraparib联合治疗BRCA或其他同源重组突变肿瘤患者的临床试验[21] 合作与发展 - 我们已经获得FDA接受GSK101的IND并获得700万美元里程碑付款[22] - 我们与GSK合作选择了Werner Helicase Inhibitor DC，目标是在2024年提交IND以进行临床评估[23] - 我们正在推进合成致死性的多个前临床研究项目，包括与GSK合作的Werner Helicase项目[28] - 公司正在与诊断领域的领军企业合作，以确定适用于产品候选人的明确定义患者人群[30] 产品研发与进展 - 公司的临床阶段产品候选药物Darovasertib是针对GNAQ或GNA11基因突变的PKC抑制剂[58] - 公司计划在2024年提名多个开发候选药物，包括用于治疗MTAP缺失固体肿瘤的候选药物[54] - Darovasertib在治疗葡萄膜黑色素瘤（UM）患者中表现出潜在的临床效果[59] - IDE397在MTAP缺失肿瘤患者中展示了临床活性[109] - IDE161在HRD实体瘤患者中展示了肿瘤缩小的初步证据[123] 合作关系 - 与Pfizer合作进行Darovasertib和crizotinib的联合治疗临床试验[66] - 与Novartis签署独家许可协议，开发和商业化IDE196（darovasertib）[182] - 与Cancer Research UK签署独家许可协议，开发和商业化PARG抑制剂[194]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4268251 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4268251 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38915 IDEAYA Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4268251 (State or oth ...

March 2023 NASDAQ: IDYA IDEAYA Biosciences Improving Lives ...